Clinical trial

Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR

NCT01744925

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Icotinib of routine dose Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Icotinib of high dose Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2012-10-01

PhasePHASE2

Conditions

Non-small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Interventions

Icotinib of routine doseDRUG

Icotinib of high doseDRUG

Sponsors & collaborators

Tianjin Medical University Cancer Institute and Hospitallead sponsor

Mapped research locations

TianjinTianjin Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01744925 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.